IN8bio, Inc.
INAB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $3 | $0 | $0 |
| Gross Profit | $0 | -$3 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $17 | $17 | $14 | $7 |
| G&A Expenses | $13 | $14 | $14 | $7 |
| SG&A Expenses | $13 | $14 | $14 | $7 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | -$3 | $0 | $0 |
| Operating Expenses | $30 | $28 | $29 | $15 |
| Operating Income | -$30 | -$30 | -$29 | -$15 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$30 | -$30 | -$29 | -$15 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$30 | -$30 | -$29 | -$15 |
| % Margin | – | – | – | – |
| EPS | -0.57 | -1 | -1.36 | -0.78 |
| % Growth | 43% | 26.5% | -74.4% | – |
| EPS Diluted | -0.57 | -1 | -1.36 | -0.78 |
| Weighted Avg Shares Out | 54 | 30 | 21 | 19 |
| Weighted Avg Shares Out Dil | 54 | 30 | 21 | 19 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $3 | $1 | $1 |
| EBITDA | -$27 | -$28 | -$27 | -$14 |
| % Margin | – | – | – | – |